About Microfluidic Devices
Microfluidics device is a technology that allows the integration of many medical tests on a single chip. It has a several applications in the field of medicine, cell biology research, and protein crystallization. Thus, microfluidic technology is an important tool to reduce side effects and improve the efficacy of treatment. It has become an important technology for integration, miniaturization, industrialization, and parallelization of various tests in the fields of diagnostics, biological research, and drug development.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Microfluidic Devices market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Danaher Corporation (United States), Thermo Fisher Scientific (United States), Agilent Technologies (United States), Fluidigm Microfluidics (United States), Bio-Rad Laboratories, Inc. (United States), Becton, Dickinson and Company (United States), Abbott Laboratories (United States), Cepheid (United States), RainDance Technologies, Inc. (United States), Dolomite Microfluidics (United Kingdom) and Micronit Microtechnologies (Netherlands) are some of the key players that are part of study coverage.
Segmentation Overview
AMA Research has segmented the market of Global Microfluidic Devices market by Type (Glass , Polymer and Silicon), Application (Pharmaceutical and Life Science Research, Clinical and Veterinary Diagnostics, Point of Care Diagnostics, Analytical Devices, Drug Delivery and Others) and Region.
On the basis of geography, the market of Microfluidic Devices has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Industry, the sub-segment i.e. In-vitro diagnostics will boost the Microfluidic Devices market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Material , the sub-segment i.e. Glass will boost the Microfluidic Devices market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Rising Number of Product Innovations
Market Growth Drivers:
Increasing R&D Investment in Pharmaceuticals, Life Science Sector and Rising Demand for Point-of-Care Testing
Challenges:
Geometrical and Surface Chemistry Issues and Standardization of Microfluidic Devices
Restraints:
Strict Regulatory Requirements
Opportunities:
Increasing Demand of Microfluidic Devices in Genomics and Proteomics and Change in the Material Mix Provides New Opportunities for New Players
Market Leaders and their expansionary development strategies
In Aug 2019, Agilent Technologies, Inc. announced it has completed the acquisition of BioTek Instruments, a global leader in the design, manufacture, and distribution of innovative life science instrumentation.
In June 2023, SCIEX, a global leader in life science analytical technologies, launched the Intabio ZT system, the first fully-integrated microfluidic chip-based platform combining imaged capillary isoelectric focusing (icIEF) separation and UV detection. When coupled with mass spectrometry (MS) identification on the ZenoTOF 7600 system, it eliminates the guesswork from early drug development stages and accelerates drug candidate selection. This icIEF-UV/MS workflow enables separation, quantitation and identification of biopharmaceutical charge variants and their proteoforms.
Key Target Audience
Microfluidic Devices Manufcatuees, Microfluidic Devices Suppliers/Distributors, Raw Material Suppliers, Potential Investors, Technology Investors, Research Firm and Others
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.